Tecartus
mayo 10, 2022
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
Menú
At Geistek, we are at the forefront of oncology clinical development, offering innovative and strategic clinical research designs transforming cancer treatment. Our expertise and innovative approaches are recognized and trusted by TOP10 BigPharma companies and numerous biotechs worldwide.
We are dedicated to advancing cancer research through innovative clinical trial designs and strategic development planning. Partner with Geistek to access our expertise, extensive network, and commitment to improving cancer treatment worldwide.
Contact us today to learn more about how we can support your oncology clinical development projects and help bring your innovative therapies to patients in need.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
